Alan Charney

Initiating Sacubitril/Valsartan (LCZ696) in Heart Failure: Results of TITRATION, a Double-Blind, Randomized Comparison of Two Uptitration Regimens

Michele Senni, John J.V. McMurray, Rolf Wachter et al. · European Journal of Heart Failure · 2016 · 236 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Hong Zhang, Dana V. Rizk, Vlado Perkovic et al. · Kidney International · 2023 · 121 citations · Full text

Medicine, Nephrology, Pharmacology +17

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

Sadayoshi Ito, Minoru Satoh, Yuko Tamaki et al. · Hypertension Research · 2015 · 105 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Systolic Blood Pressure on the Safety and Tolerability of Initiating and Up-Titrating Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Insights from the TITRATION Study

Michele Senni, John J.V. McMurray, Rolf Wachter et al. · European Journal of Heart Failure · 2017 · 70 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +11

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Dana V. Rizk, Brad H. Rovin, Hong Zhang et al. · Kidney International Reports · 2023 · 60 citations · Full text

Medicine, Immunology, Nephrology +15